Plerixafor: a peripheral blood stem cell mobilizer.

Area of Science:

• Hematology
• Pharmacology
• Oncology

Background:

• Autologous hematopoietic stem cell (HSC) transplantation is crucial for treating hematologic malignancies.
• Successful transplantation relies on adequate CD34(+) cell yield, predicted by stem cell mobilization.
• Current mobilization methods like G-CSF +/- chemotherapy are ineffective in 5-30% of patients.

Purpose of the Study:

• To evaluate Plerixafor as a novel agent for HSC mobilization.
• To assess the efficacy of Plerixafor in combination with G-CSF for stem cell collection.
• To explore Plerixafor's role in salvage therapy for poor mobilizers.

Main Methods:

• Plerixafor antagonizes SDF-1alpha/CXCR4 binding to enhance HSC mobilization.
• Clinical trials investigated Plerixafor plus G-CSF for HSC collection in NHL and MM.
• Studies also examined Plerixafor's use in Hodgkin's lymphoma and as a salvage treatment.

Main Results:

• Plerixafor plus G-CSF facilitated high HSC yields with fewer apheresis sessions in NHL and MM.
• Promising results were observed in Hodgkin's lymphoma patients.
• Plerixafor with G-CSF proved effective as a salvage strategy for G-CSF-resistant patients.

Conclusions:

• Plerixafor in combination with G-CSF is an effective HSC mobilization strategy.
• It offers a viable option for patients unresponsive to standard G-CSF mobilization.
• Further research is needed to compare Plerixafor regimens with chemotherapy and assess cost-effectiveness.